X
PTGX icon

Xponance’s Protagonist Therapeutics PTGX Stock Holding History

Xponance’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$743K Buy
6,062
+590
+11% +$61.6K ﹤0.01% 914
2026
Q1 		$577K Buy
5,472
+884
+19% +$78.3K ﹤0.01% 954
2025
Q4 		$401K Buy
4,588
+54
+1% +$4.42K ﹤0.01% 1035
2025
Q3 		$301K Buy
4,534
+28
+0.6% +$1.59K ﹤0.01% 1159
2025
Q2 		$249K Buy
4,506
+42
+0.9% +$2.02K ﹤0.01% 1222
2025
Q1 		$216K Buy
+4,464
New +$187K ﹤0.01% 1243

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Xponance's PTGX Position: Q2 2026 in Review

Xponance increased its Protagonist Therapeutics (PTGX) stake by 11% in Q2 2026, buying an estimated $61.6K and bringing the position to 6,062 shares worth $743K. The position accounts for ﹤0.01% of the portfolio, ranked #914.

Xponance first reported a position in PTGX in Q1 2025 and has held it in 6 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Xponance held 6,062 shares of Protagonist Therapeutics worth $743K as of Q2 2026.
  • Xponance bought 590 Protagonist Therapeutics shares in Q2 2026, an estimated $61.6K.
  • Protagonist Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #914 holding.
  • Xponance first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.